sulforaphane has been researched along with Prostatic Neoplasms in 69 studies
sulforaphane: from Cardaria draba L.
sulforaphane : An isothiocyanate having a 4-(methylsulfinyl)butyl group attached to the nitrogen.
Prostatic Neoplasms: Tumors or cancer of the PROSTATE.
| Excerpt | Relevance | Reference |
|---|---|---|
| " We have shown previously that prostate cancer prevention by sulforaphane (SFN) in Transgenic Adenocarcinoma of Mouse Prostate (TRAMP) model is associated with inhibition of fatty acid metabolism." | 3.91 | Reversal of the Warburg phenomenon in chemoprevention of prostate cancer by sulforaphane. ( Alumkal, JJ; Foley, LM; Hahm, ER; Hitchens, TK; Jacobs, BL; Parikh, RA; Shiva, SS; Singh, KB; Singh, SV, 2019) |
| " We have shown previously that oral administration of sulforaphane (SFN) significantly inhibits the incidence and/or burden of prostatic intraepithelial neoplasia and well-differentiated adenocarcinoma in TRansgenic Adenocarcinoma of Mouse Prostate (TRAMP) mice." | 3.88 | Prostate cancer chemoprevention by sulforaphane in a preclinical mouse model is associated with inhibition of fatty acid metabolism. ( Hahm, ER; Jacobs, BL; Kim, SH; Pore, SK; Singh, KB; Singh, SV, 2018) |
| "The increasing incidence of prostate cancer worldwide has spurred research into novel therapeutics for its treatment and prevention." | 3.01 | Sulforaphane and Its Protective Role in Prostate Cancer: A Mechanistic Approach. ( Ahmad, I; Mordecai, J; Ullah, S, 2023) |
| "Sulforaphane is a constituent of these foods postulated to harbor the anti-neoplastic activity based on multiple tumor models." | 2.80 | A phase II study of sulforaphane-rich broccoli sprout extracts in men with recurrent prostate cancer. ( Alumkal, JJ; Beer, TM; Cherala, G; Flamiatos, JF; Gao, L; Gibbs, A; Graff, JN; Kleinschmidt, R; Koop, DR; Mori, M; Munar, M; Ryan, CW; Schwartzman, J; Slottke, R; Tucker, E, 2015) |
| "Sulforaphane effects were prominent after 3 months of intervention (M3-M6)." | 2.80 | Effect of Sulforaphane in Men with Biochemical Recurrence after Radical Prostatectomy. ( Azzouzi, AR; Cipolla, BG; Coadou, Y; Corbel, L; Della Negra, E; Le Scodan, R; Lefort, JM; Mandron, E; Mottet, N, 2015) |
| "Here, we show that the prostate cancer stem cell (pCSC)-like traits, such as accelerated activity of aldehyde dehydrogenase 1 (ALDH1), enrichment of CD49f+ fraction, and sphere forming efficiency, are attenuated by SFN treatment." | 1.43 | Sulforaphane Inhibits c-Myc-Mediated Prostate Cancer Stem-Like Traits. ( Hahm, ER; Moura, MB; Singh, KB; Singh, SV; Vyas, AR, 2016) |
| "Exposure of prostate cancer cells (LNCaP, 22Rv1, C4-2, and PC-3) to pharmacologically applicable concentrations of PEITC, benzyl isothiocyanate (BITC), and SFN (2." | 1.42 | CXCR4 is a novel target of cancer chemopreventative isothiocyanates in prostate cancer cells. ( Amjad, AI; Chinni, SR; Parikh, R; Sakao, K; Singh, SV; Vyas, AR, 2015) |
| "Advanced prostate cancer has highly invasive potential, which may lead to metastasis associated with poor prognosis." | 1.42 | Sulforaphane inhibits invasion by phosphorylating ERK1/2 to regulate E-cadherin and CD44v6 in human prostate cancer DU145 cells. ( Geng, Y; Li, C; Peng, X; Tian, H; Wu, S; Wu, W; Yang, G; Zhou, Y, 2015) |
| "D,L-Sulforaphane (SFN) is a promising chemopreventive agent with in vivo efficacy against prostate cancer in experimental rodents." | 1.40 | Functional relevance of D,L-sulforaphane-mediated induction of vimentin and plasminogen activator inhibitor-1 in human prostate cancer cells. ( Singh, SV; Vyas, AR, 2014) |
| "Advanced androgen-independent prostate cancer (AIPC) is an aggressive malignancy with a poor prognosis." | 1.40 | Sulforaphane and TRAIL induce a synergistic elimination of advanced prostate cancer stem-like cells. ( Aleksandrowicz, E; Bauer, N; Gladkich, J; Herr, I; Labsch, S; Liu, L; Schönsiegel, F; Zhang, Y, 2014) |
| "Sulforaphane (SFN) is a phytochemical derived from cruciferous vegetables that induces anti-proliferative and pro-apoptotic responses in prostate cancer cells, but not in normal prostate cells." | 1.40 | Transcriptome analysis reveals a dynamic and differential transcriptional response to sulforaphane in normal and prostate cancer cells and suggests a role for Sp1 in chemoprevention. ( Beaver, LM; Buchanan, A; Chang, JH; Dashwood, RH; Ho, E; Löhr, CV; Riscoe, AN; Sokolowski, EI; Williams, DE; Wong, CP, 2014) |
| "Erucin (ER) is a dietary ITC, which has been recently considered a promising cancer chemopreventive phytochemical." | 1.39 | Antiproliferative activity of the dietary isothiocyanate erucin, a bioactive compound from cruciferous vegetables, on human prostate cancer cells. ( Catania, S; Costa, C; Francisco, M; Maimone, P; Melchini, A; Miceli, N; Mithen, RF; Taviano, MF; Traka, MH, 2013) |
| "Sulforaphane (SFN) is a compound derived from cruciferous plants." | 1.38 | Sulforaphane, a cruciferous vegetable-derived isothiocyanate, inhibits protein synthesis in human prostate cancer cells. ( Herman-Antosiewicz, A; Hofman, D; Konopa, G; Wiczk, A, 2012) |
| "Exposure of human prostate cancer cells (PC-3, LNCaP, and/or LNCaP-C4-2B) to SFN as well as its naturally-occurring thio-, sulfinyl-, and sulfonyl-analogs resulted in cleavage (activation) of Notch1, Notch2, and Notch4, which was accompanied by a decrease in levels of full-length Notch forms especially at the 16- and 24-hour time points." | 1.38 | Notch activation is dispensable for D, L-sulforaphane-mediated inhibition of human prostate cancer cell migration. ( Amin, S; Chandra-Kuntal, K; Desai, D; Hahm, ER; Singh, SV, 2012) |
| "Sulforaphane (SFN) is an isothiocyanate derived from cruciferous vegetables such as broccoli." | 1.37 | Differential effects of sulforaphane on histone deacetylases, cell cycle arrest and apoptosis in normal prostate cells versus hyperplastic and cancerous prostate cells. ( Clarke, JD; Dashwood, RH; Ho, E; Hsu, A; Yu, Z, 2011) |
| "Hydrogen sulfide (H(2)S) is a novel gasotransmitter that regulates cell proliferation and other cellular functions." | 1.37 | Hydrogen sulfide mediates the anti-survival effect of sulforaphane on human prostate cancer cells. ( Cao, Q; Pei, Y; Wu, B; Wu, L; Yang, G, 2011) |
| "Prostate cancer is a polyfactorial molecular anomaly that is offering refractoriness against a broad range of therapeutic drugs." | 1.37 | Shattering the underpinnings of neoplastic architecture in LNCap: synergistic potential of nutraceuticals in dampening PDGFR/EGFR signaling and cellular proliferation. ( Ahsan, Qu; Asif, H; Bhatti, S; Dilawar, BA; Farooqi, AA; Fayyaz, S; Javed, Z; Javeed, MK; Khanum, R; Mansoor, Q; Nisar, K; Rana, A; Riaz, AM, 2011) |
| "Sulforaphane was also found to inhibit hypoxia induced HIF-1alpha expression through activating JNK and ERK signaling pathways, but not AKT pathway." | 1.35 | Sulforaphane inhibited expression of hypoxia-inducible factor-1alpha in human tongue squamous cancer cells and prostate cancer cells. ( Jiang, BH; Luo, J; Shi, X; Wang, H; Yao, H; Zhang, Z, 2008) |
| "Prostate cancer is thought to arise as a result of oxidative stresses and induction of antioxidant electrophile defense (phase 2) enzymes has been proposed as a prostate cancer prevention strategy." | 1.35 | Temporal changes in gene expression induced by sulforaphane in human prostate cancer cells. ( Bhamre, S; Brooks, JD; Dill, DL; Sahoo, D; Tibshirani, R, 2009) |
| "Markers of apoptosis, angiogenesis, and metastasis were measured by immunohistochemistry." | 1.35 | Sulforaphane enhances the therapeutic potential of TRAIL in prostate cancer orthotopic model through regulation of apoptosis, metastasis, and angiogenesis. ( Ganapathy, S; Shankar, S; Srivastava, RK, 2008) |
| "AR is the central signaling pathway in prostate cancer, and its inhibition is used for both prevention and treatment of this disease." | 1.35 | Sulforaphane destabilizes the androgen receptor in prostate cancer cells by inactivating histone deacetylase 6. ( Alumkal, J; Deng, V; Gibbs, A; Schwartzman, J, 2009) |
| "During prostate cancer progression, specific modifications in acetylation patterns on histones are apparent." | 1.35 | Dietary sulforaphane, a histone deacetylase inhibitor for cancer prevention. ( Clarke, JD; Dashwood, RH; Ho, E, 2009) |
| "Using PC-3 and DU145 human prostate cancer cells as a model, we now demonstrate, for the first time, that the initial signal for SFN-induced apoptosis is derived from reactive oxygen species (ROS)." | 1.33 | Sulforaphane-induced cell death in human prostate cancer cells is initiated by reactive oxygen species. ( Antosiewicz, J; Choi, S; Herman-Antosiewicz, A; Johnson, CS; Lee, YJ; Lew, KL; Singh, SV; Srivastava, SK; Trump, DL; Watkins, SC; Xiao, D; Xiao, H; Zeng, Y, 2005) |
| "Sulforaphane (SFN) is a major isothiocyanate compound in cruciferous vegetables such as broccoli, cauliflower, and Brussels sprouts." | 1.33 | Involvement of c-Jun N-terminal kinase in G2/M arrest and caspase-mediated apoptosis induced by sulforaphane in DU145 prostate cancer cells. ( Cho, SD; Hu, H; Jiang, C; Kang, KS; Kim, SH; Lee, YS; Li, G; Lu, J, 2005) |
| "PC-3 prostate cancer cells were cultured in 96-well microtitre plates." | 1.32 | The effect of indole-3-carbinol and sulforaphane on a prostate cancer cell line. ( Frydoonfar, HR; McGrath, DR; Spigelman, AD, 2003) |
| "is inversely related to prostate cancer risk, although the mechanism of prevention and the responsible phytochemicals are unknown." | 1.32 | Targeting cell cycle machinery as a molecular mechanism of sulforaphane in prostate cancer prevention. ( Ahmed, T; Chiao, JW; Chung, FL; Conaway, C; Liu, D; Wang, L, 2004) |
| "The human prostate cancer cell lines LNCaP, MDA PCa 2a, MDA PCa 2b, PC-3, and TSU-Pr1 were treated with 0." | 1.31 | Potent induction of phase 2 enzymes in human prostate cells by sulforaphane. ( Brooks, JD; Paton, VG; Vidanes, G, 2001) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 24 (34.78) | 29.6817 |
| 2010's | 39 (56.52) | 24.3611 |
| 2020's | 6 (8.70) | 2.80 |
| Authors | Studies |
|---|---|
| Melchini, A | 6 |
| Needs, PW | 3 |
| Mithen, RF | 8 |
| Traka, MH | 8 |
| Livingstone, TL | 1 |
| Saha, S | 3 |
| Bernuzzi, F | 2 |
| Savva, GM | 2 |
| Troncoso-Rey, P | 2 |
| Mills, RD | 5 |
| Ball, RY | 5 |
| Mordecai, J | 1 |
| Ullah, S | 1 |
| Ahmad, I | 1 |
| Tuttis, K | 1 |
| Machado, ART | 1 |
| Santos, PWDS | 1 |
| Antunes, LMG | 1 |
| Coode-Bate, J | 2 |
| Sivapalan, T | 1 |
| Dainty, JR | 2 |
| Maicha, JB | 1 |
| Beasy, G | 1 |
| Singh, KB | 4 |
| Hahm, ER | 8 |
| Alumkal, JJ | 2 |
| Foley, LM | 1 |
| Hitchens, TK | 1 |
| Shiva, SS | 1 |
| Parikh, RA | 1 |
| Jacobs, BL | 2 |
| Singh, SV | 17 |
| Carrasco-Pozo, C | 1 |
| Tan, KN | 1 |
| Rodriguez, T | 1 |
| Avery, VM | 1 |
| Kim, SH | 4 |
| Powolny, AA | 3 |
| Rutz, J | 1 |
| Thaler, S | 1 |
| Maxeiner, S | 1 |
| Chun, FK | 1 |
| Blaheta, RA | 1 |
| Zhou, Y | 3 |
| Yang, G | 4 |
| Tian, H | 3 |
| Hu, Y | 2 |
| Wu, S | 3 |
| Geng, Y | 3 |
| Lin, K | 2 |
| Wu, W | 3 |
| Pore, SK | 1 |
| Ferreira, PMP | 1 |
| Rodrigues, LARL | 1 |
| de Alencar Carnib, LP | 1 |
| de Lima Sousa, PV | 1 |
| Nolasco Lugo, LM | 1 |
| Nunes, NMF | 1 |
| do Nascimento Silva, J | 1 |
| da Silva Araûjo, L | 1 |
| de Macêdo Gonçalves Frota, K | 1 |
| Al Kadhi, O | 1 |
| Defernez, M | 1 |
| Kibblewhite, H | 1 |
| O'Neill, CM | 1 |
| Mythen, L | 1 |
| Hughes, J | 1 |
| Cooper, CS | 1 |
| Zhang, Z | 2 |
| Garzotto, M | 1 |
| Davis, EW | 1 |
| Mori, M | 2 |
| Stoller, WA | 1 |
| Farris, PE | 1 |
| Wong, CP | 4 |
| Beaver, LM | 4 |
| Thomas, GV | 1 |
| Williams, DE | 5 |
| Dashwood, RH | 8 |
| Hendrix, DA | 2 |
| Ho, E | 9 |
| Shannon, J | 1 |
| Zhang, C | 1 |
| Su, ZY | 1 |
| Khor, TO | 2 |
| Shu, L | 1 |
| Kong, AN | 4 |
| Vyas, AR | 4 |
| Arlotti, JA | 2 |
| Watkins, S | 1 |
| Stolz, DB | 1 |
| Desai, D | 4 |
| Amin, S | 4 |
| Hsu, A | 3 |
| Buchanan, A | 3 |
| Palomera-Sanchez, Z | 2 |
| Houseman, EA | 1 |
| Labsch, S | 2 |
| Liu, L | 1 |
| Bauer, N | 1 |
| Zhang, Y | 1 |
| Aleksandrowicz, E | 1 |
| Gladkich, J | 2 |
| Schönsiegel, F | 1 |
| Herr, I | 2 |
| Sokolowski, EI | 1 |
| Riscoe, AN | 1 |
| Chang, JH | 2 |
| Löhr, CV | 2 |
| Canapè, C | 1 |
| Catanzaro, G | 1 |
| Terreno, E | 1 |
| Karlsson, M | 1 |
| Lerche, MH | 1 |
| Jensen, PR | 1 |
| Slottke, R | 1 |
| Schwartzman, J | 2 |
| Cherala, G | 1 |
| Munar, M | 1 |
| Graff, JN | 1 |
| Beer, TM | 1 |
| Ryan, CW | 1 |
| Koop, DR | 1 |
| Gibbs, A | 2 |
| Gao, L | 1 |
| Flamiatos, JF | 1 |
| Tucker, E | 1 |
| Kleinschmidt, R | 1 |
| Sakao, K | 1 |
| Chinni, SR | 1 |
| Amjad, AI | 1 |
| Parikh, R | 1 |
| Cipolla, BG | 1 |
| Mandron, E | 1 |
| Lefort, JM | 1 |
| Coadou, Y | 1 |
| Della Negra, E | 1 |
| Corbel, L | 1 |
| Le Scodan, R | 1 |
| Azzouzi, AR | 1 |
| Mottet, N | 1 |
| Hać, A | 1 |
| Domachowska, A | 1 |
| Narajczyk, M | 1 |
| Cyske, K | 1 |
| Pawlik, A | 1 |
| Herman-Antosiewicz, A | 7 |
| Watson, GW | 1 |
| Wickramasekara, S | 1 |
| Fang, Y | 1 |
| Maier, CS | 1 |
| Perez, VI | 1 |
| Peng, X | 1 |
| Li, C | 1 |
| Abbas, A | 1 |
| Hall, JA | 1 |
| Patterson, WL | 1 |
| Al-Mulla, F | 1 |
| Georgel, PT | 1 |
| van Die, MD | 1 |
| Bone, KM | 1 |
| Emery, J | 1 |
| Williams, SG | 1 |
| Pirotta, MV | 1 |
| Paller, CJ | 1 |
| Moura, MB | 1 |
| Ganai, SA | 1 |
| Negrette-Guzmán, M | 1 |
| Huerta-Yepez, S | 1 |
| Vega, MI | 1 |
| León-Contreras, JC | 1 |
| Hernández-Pando, R | 1 |
| Medina-Campos, ON | 1 |
| Rodríguez, E | 1 |
| Tapia, E | 1 |
| Pedraza-Chaverri, J | 1 |
| Kuintzle, R | 1 |
| Wiley, MW | 1 |
| Glasser, ST | 1 |
| Johnson, GS | 1 |
| Yao, H | 1 |
| Wang, H | 1 |
| Jiang, BH | 1 |
| Luo, J | 1 |
| Shi, X | 1 |
| Bhamre, S | 1 |
| Sahoo, D | 1 |
| Tibshirani, R | 1 |
| Dill, DL | 1 |
| Brooks, JD | 2 |
| Shankar, S | 1 |
| Ganapathy, S | 1 |
| Srivastava, RK | 1 |
| Shabbeer, S | 1 |
| Sobolewski, M | 1 |
| Anchoori, RK | 1 |
| Kachhap, S | 1 |
| Hidalgo, M | 1 |
| Jimeno, A | 1 |
| Davidson, N | 1 |
| Carducci, MA | 1 |
| Khan, SR | 1 |
| Warin, R | 1 |
| Xiao, D | 5 |
| Stan, SD | 1 |
| Zeng, Y | 3 |
| Marynowski, SW | 1 |
| Bommareddy, A | 2 |
| Parise, RA | 1 |
| Beumer, JH | 1 |
| Chambers, WH | 1 |
| Antosiewicz, J | 2 |
| Chambers, KF | 1 |
| Bacon, JR | 1 |
| Kemsley, EK | 1 |
| Deng, V | 1 |
| Alumkal, J | 1 |
| Clarke, JD | 2 |
| Spinks, CA | 1 |
| Doleman, JF | 1 |
| Nair, S | 2 |
| Barve, A | 1 |
| Shen, GX | 1 |
| Lin, W | 1 |
| Chan, JY | 1 |
| Cai, L | 1 |
| Kallifatidis, G | 1 |
| Rausch, V | 1 |
| Mattern, J | 1 |
| Moldenhauer, G | 1 |
| Büchler, MW | 1 |
| Salnikov, AV | 1 |
| Appendino, G | 1 |
| Bardelli, A | 1 |
| Yu, Z | 1 |
| Pei, Y | 1 |
| Wu, B | 1 |
| Cao, Q | 1 |
| Wu, L | 1 |
| Farooqi, AA | 1 |
| Bhatti, S | 1 |
| Rana, A | 1 |
| Fayyaz, S | 1 |
| Mansoor, Q | 1 |
| Javed, Z | 1 |
| Riaz, AM | 1 |
| Nisar, K | 1 |
| Ahsan, Qu | 1 |
| Dilawar, BA | 1 |
| Asif, H | 1 |
| Khanum, R | 1 |
| Javeed, MK | 1 |
| Wiczk, A | 1 |
| Hofman, D | 1 |
| Konopa, G | 1 |
| Chandra-Kuntal, K | 1 |
| Catania, S | 1 |
| Miceli, N | 1 |
| Taviano, MF | 1 |
| Maimone, P | 1 |
| Francisco, M | 1 |
| Costa, C | 1 |
| Frydoonfar, HR | 1 |
| McGrath, DR | 1 |
| Spigelman, AD | 1 |
| Singh, AV | 1 |
| Lew, KL | 4 |
| Dhir, R | 1 |
| Wang, L | 1 |
| Liu, D | 1 |
| Ahmed, T | 2 |
| Chung, FL | 2 |
| Conaway, C | 1 |
| Chiao, JW | 2 |
| Choi, S | 3 |
| Srivastava, SK | 1 |
| Watkins, SC | 1 |
| Johnson, CS | 1 |
| Trump, DL | 1 |
| Lee, YJ | 1 |
| Xiao, H | 3 |
| Xu, C | 2 |
| Shen, G | 2 |
| Chen, C | 1 |
| Gélinas, C | 1 |
| Cho, SD | 1 |
| Li, G | 1 |
| Hu, H | 1 |
| Jiang, C | 1 |
| Kang, KS | 1 |
| Lee, YS | 1 |
| Lu, J | 1 |
| Yuan, X | 1 |
| Kim, JH | 1 |
| Gopalkrishnan, A | 1 |
| Keum, YS | 1 |
| Myzak, MC | 1 |
| Hardin, K | 1 |
| Wang, R | 1 |
| Johnson, DE | 1 |
| Brown, CK | 1 |
| Paton, VG | 1 |
| Vidanes, G | 1 |
| Kancherla, R | 1 |
| Mittelman, A | 1 |
| Conaway, CC | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| A Pre-Biopsy Window of Opportunity Trial to Measure Sulphate Levels in Human Prostate After Broccoli Consumption[NCT02821728] | 18 participants (Actual) | Interventional | 2016-04-30 | Completed | |||
| A Human Dietary Intervention Study to Investigate the Effect of Sulforaphane on Prostate Cancer Interception[NCT01950143] | 61 participants (Actual) | Interventional | 2013-08-31 | Completed | |||
| Chemoprevention of Prostate Cancer, HDAC Inhibition and DNA Methylation[NCT01265953] | 98 participants (Actual) | Interventional | 2011-07-31 | Completed | |||
| Comparison of Duration of Treatment Interruption With or Without Curcumin During the Off Treatment Periods in Patients With Prostate Cancer Undergoing Intermittent Androgen Deprivation Therapy : a Randomized, Double Blind, Placebo-controlled Trial[NCT03211104] | 107 participants (Actual) | Interventional | 2007-08-30 | Completed | |||
| A Human Intervention Trial Studying Gene Expression in High-Grade Prostatic Intraepithelial Neoplasia Following Consumption of Broccoli or Peas[NCT00535977] | 22 participants (Actual) | Interventional | 2005-04-30 | Completed | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
In subjects at risk for prostate cancer, presence of SFN was analyzed in plasma. Collection of blood specimens occurred at pre-intervention and post-intervention. The Change = post-intervention level minus pre-intervention level (NCT01265953)
Timeframe: Baseline and 4-8 weeks following intervention
| Intervention | micromolar (µM) (Mean) |
|---|---|
| Supplement | 0.12 |
| Placebo | -0.0003 |
Collection of blood and urine specimens occurred at pre-intervention and post-intervention. Change = post-intervention level minus pre-intervention level (NCT01265953)
Timeframe: Baseline and 4-8 weeks following intervention
| Intervention | micromolar (µM) concentrations of urina (Mean) |
|---|---|
| Supplement | 4.75 |
| Placebo | -0.02 |
Immunohistochemical (IHC) analysis of HDAC6 expression using research-only prostate biopsy tissue collected post-intervention at the time of the clinically-indicated prostate biopsy. A modified Histo-score (H-score) was calculated, which involved semiquantitative assessment of both staining intensity (graded as 1-3 with 1 representing weak staining, 2 moderate, and 3 strong) and percentage of positive cells. H-score ranged from 0 to 300 with 300 the strongest expression. (NCT01265953)
Timeframe: Baseline and 4-8 weeks following intervention; prostate biopsy were collected post-intervention when clinically-indicated
| Intervention | H-score (Mean) |
|---|---|
| Supplement | 187 |
| Placebo | 183 |
Ki67 is a biomarker of disease progression. Immunohistochemical (IHC) analysis of Ki67 was performed using research only prostate biopsy specimens collected post-intervention at the time of the clinically-indicated prostate biopsy. (NCT01265953)
Timeframe: Baseline and 4-8 weeks following intervention; prostate biopsy were collected post-intervention when clinically-indicated
| Intervention | percent positive (Mean) |
|---|---|
| Supplement | 1.8 |
| Placebo | 1.9 |
5 reviews available for sulforaphane and Prostatic Neoplasms
| Article | Year |
|---|---|
Sulforaphane and Its Protective Role in Prostate Cancer: A Mechanistic Approach.
Topics: Brassica; Humans; Isothiocyanates; Male; Prostatic Neoplasms; Sulfoxides | 2023 |
Cruciferous Vegetables as Antioxidative, Chemopreventive and Antineoplasic Functional Foods: Preclinical and Clinical Evidences of Sulforaphane Against Prostate Cancers.
Topics: Animals; Antineoplastic Agents, Phytogenic; Antioxidants; Brassicaceae; Functional Food; Humans; Iso | 2018 |
Sulforaphane and prostate cancer interception.
Topics: Animals; Anticarcinogenic Agents; Brassica; Diet; Disease Models, Animal; Disease Progression; Human | 2014 |
Phytotherapeutic interventions in the management of biochemically recurrent prostate cancer: a systematic review of randomised trials.
Topics: Antineoplastic Agents, Phytogenic; Brassica; Carotenoids; Curcuma; Glycine max; Humans; Isothiocyana | 2016 |
Histone deacetylase inhibitor sulforaphane: The phytochemical with vibrant activity against prostate cancer.
Topics: Antineoplastic Agents; Biological Availability; Histone Deacetylase Inhibitors; Humans; Isothiocyana | 2016 |
5 trials available for sulforaphane and Prostatic Neoplasms
| Article | Year |
|---|---|
Accumulation of Sulforaphane and Alliin in Human Prostate Tissue.
Topics: Allium; Antioxidants; Brassica; Cysteine; Glucosinolates; Humans; Imidoesters; Isothiocyanates; Male | 2022 |
Transcriptional changes in prostate of men on active surveillance after a 12-mo glucoraphanin-rich broccoli intervention-results from the Effect of Sulforaphane on prostate CAncer PrEvention (ESCAPE) randomized controlled trial.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Brassica; Gene Expression; Glucosinolates; Humans; Imido | 2019 |
Sulforaphane Bioavailability and Chemopreventive Activity in Men Presenting for Biopsy of the Prostate Gland: A Randomized Controlled Trial.
Topics: Aged; Anticarcinogenic Agents; Biological Availability; Biomarkers, Tumor; Biopsy; Brassica; Chemopr | 2020 |
A phase II study of sulforaphane-rich broccoli sprout extracts in men with recurrent prostate cancer.
Topics: Area Under Curve; Brassica; Chromatography, Liquid; Dose-Response Relationship, Drug; Glutathione Tr | 2015 |
Effect of Sulforaphane in Men with Biochemical Recurrence after Radical Prostatectomy.
Topics: Aged; Anticarcinogenic Agents; Double-Blind Method; Follow-Up Studies; Humans; Isothiocyanates; Male | 2015 |
59 other studies available for sulforaphane and Prostatic Neoplasms
| Article | Year |
|---|---|
Enhanced in vitro biological activity of synthetic 2-(2-pyridyl) ethyl isothiocyanate compared to natural 4-(methylsulfinyl) butyl isothiocyanate.
Topics: Anticarcinogenic Agents; Apoptosis; Biomarkers, Tumor; Blotting, Western; Brassica; Cell Proliferati | 2012 |
Sulforaphane Combined with Vitamin D Induces Cytotoxicity Mediated by Oxidative Stress, DNA Damage, Autophagy, and JNK/MAPK Pathway Modulation in Human Prostate Tumor Cells.
Topics: Apoptosis; Autophagy; bcl-2-Associated X Protein; Cell Line, Tumor; DNA Damage; Humans; Male; NF-E2- | 2023 |
Accumulation of Dietary S-Methyl Cysteine Sulfoxide in Human Prostate Tissue.
Topics: Aged; Allium; Brassica; Dietary Supplements; Glucosinolates; Humans; Imidoesters; Isothiocyanates; M | 2019 |
Reversal of the Warburg phenomenon in chemoprevention of prostate cancer by sulforaphane.
Topics: Adenocarcinoma; Animals; Anticarcinogenic Agents; Chemoprevention; Glycolysis; Humans; Isothiocyanat | 2019 |
The Molecular Effects of Sulforaphane and Capsaicin on Metabolism upon Androgen and Tip60 Activation of Androgen Receptor.
Topics: Androgens; bcl-X Protein; Capsaicin; Cell Line, Tumor; Cell Nucleus; Cell Proliferation; Gene Expres | 2019 |
The Role of Lysosome-associated Membrane Protein 2 in Prostate Cancer Chemopreventive Mechanisms of Sulforaphane.
Topics: Adenocarcinoma; Animals; Anticarcinogenic Agents; Apoptosis; Autophagy; Cell Line, Tumor; Disease Mo | 2020 |
Sulforaphane Reduces Prostate Cancer Cell Growth and Proliferation In Vitro by Modulating the Cdk-Cyclin Axis and Expression of the CD44 Variants 4, 5, and 7.
Topics: Acetylation; Anticarcinogenic Agents; Cell Line, Tumor; Cell Proliferation; Cyclin-Dependent Kinases | 2020 |
Sulforaphane metabolites cause apoptosis via microtubule disruption in cancer.
Topics: Anticarcinogenic Agents; Apoptosis; Caspase 3; Cell Line, Tumor; Humans; Isothiocyanates; Male; MAP | 2018 |
Prostate cancer chemoprevention by sulforaphane in a preclinical mouse model is associated with inhibition of fatty acid metabolism.
Topics: Adenocarcinoma; Animals; Anticarcinogenic Agents; Chemoprevention; Fatty Acid Synthases; Fatty Acids | 2018 |
Sulforaphane enhances Nrf2 expression in prostate cancer TRAMP C1 cells through epigenetic regulation.
Topics: Animals; Anticarcinogenic Agents; Cell Line, Tumor; CpG Islands; Epigenesis, Genetic; Isothiocyanate | 2013 |
Chemoprevention of prostate cancer by d,l-sulforaphane is augmented by pharmacological inhibition of autophagy.
Topics: Animals; Anticarcinogenic Agents; Antimalarials; Antineoplastic Combined Chemotherapy Protocols; Apo | 2013 |
Functional relevance of D,L-sulforaphane-mediated induction of vimentin and plasminogen activator inhibitor-1 in human prostate cancer cells.
Topics: Adenocarcinoma; Animals; Anticarcinogenic Agents; Apoptosis; Cadherins; Cell Line; Cell Line, Tumor; | 2014 |
Effects of sulforaphane and 3,3'-diindolylmethane on genome-wide promoter methylation in normal prostate epithelial cells and prostate cancer cells.
Topics: Analysis of Variance; Anticarcinogenic Agents; Cells, Cultured; Chromatin Immunoprecipitation; DNA M | 2014 |
Sulforaphane and TRAIL induce a synergistic elimination of advanced prostate cancer stem-like cells.
Topics: Animals; Antineoplastic Agents; Cell Death; Cell Line, Tumor; Chick Embryo; Drug Synergism; Humans; | 2014 |
Transcriptome analysis reveals a dynamic and differential transcriptional response to sulforaphane in normal and prostate cancer cells and suggests a role for Sp1 in chemoprevention.
Topics: Anticarcinogenic Agents; Carcinogenesis; Cell Line, Tumor; Cells, Cultured; Chemoprevention; Dietary | 2014 |
Probing treatment response of glutaminolytic prostate cancer cells to natural drugs with hyperpolarized [5-(13) C]glutamine.
Topics: Anticarcinogenic Agents; Antineoplastic Agents, Phytogenic; Biomarkers, Tumor; Carbon Isotopes; Cell | 2015 |
CXCR4 is a novel target of cancer chemopreventative isothiocyanates in prostate cancer cells.
Topics: Adenocarcinoma; Animals; Anticarcinogenic Agents; Cell Line, Tumor; Chemoprevention; Humans; Isothio | 2015 |
S6K1 controls autophagosome maturation in autophagy induced by sulforaphane or serum deprivation.
Topics: Animals; Anticarcinogenic Agents; Autophagy; Cell Line, Tumor; Culture Media, Serum-Free; Fibroblast | 2015 |
Analysis of autophagic flux in response to sulforaphane in metastatic prostate cancer cells.
Topics: Apoptosis; Autophagy; Cell Death; Cell Line, Tumor; Dose-Response Relationship, Drug; Humans; Isothi | 2015 |
Sulforaphane inhibits invasion by phosphorylating ERK1/2 to regulate E-cadherin and CD44v6 in human prostate cancer DU145 cells.
Topics: Cadherins; Cell Line, Tumor; Gene Expression Regulation, Neoplastic; Humans; Hyaluronan Receptors; I | 2015 |
Sulforaphane modulates telomerase activity via epigenetic regulation in prostate cancer cell lines.
Topics: Acetylation; Cell Line, Tumor; Chromatin; Chromatin Immunoprecipitation; Epigenesis, Genetic; Histon | 2016 |
Sulforaphane Inhibits c-Myc-Mediated Prostate Cancer Stem-Like Traits.
Topics: Animals; Anticarcinogenic Agents; Apoptosis; Blotting, Western; Cell Proliferation; Humans; Immunoen | 2016 |
Sulforaphane-cysteine suppresses invasion via downregulation of galectin-1 in human prostate cancer DU145 and PC3 cells.
Topics: Anticarcinogenic Agents; Cell Line, Tumor; Cell Proliferation; Cell Survival; Cysteine; Down-Regulat | 2016 |
Sulforaphane induces differential modulation of mitochondrial biogenesis and dynamics in normal cells and tumor cells.
Topics: Antineoplastic Agents; Antioxidants; Apoptosis; Blotting, Western; Cells, Cultured; Humans; Isothioc | 2017 |
Long noncoding RNAs and sulforaphane: a target for chemoprevention and suppression of prostate cancer.
Topics: Anticarcinogenic Agents; Cell Line, Tumor; Gene Expression Regulation, Neoplastic; Humans; Isothiocy | 2017 |
Sulforaphane inhibited expression of hypoxia-inducible factor-1alpha in human tongue squamous cancer cells and prostate cancer cells.
Topics: Anticarcinogenic Agents; Blotting, Western; Cell Line, Tumor; Extracellular Signal-Regulated MAP Kin | 2008 |
Temporal changes in gene expression induced by sulforaphane in human prostate cancer cells.
Topics: Anticarcinogenic Agents; Cell Cycle; Cell Division; G2 Phase; Gene Expression Profiling; Gene Expres | 2009 |
Sulforaphane enhances the therapeutic potential of TRAIL in prostate cancer orthotopic model through regulation of apoptosis, metastasis, and angiogenesis.
Topics: Animals; Apoptosis; Cell Proliferation; Disease Models, Animal; Drug Synergism; Isothiocyanates; Mal | 2008 |
Fenugreek: a naturally occurring edible spice as an anticancer agent.
Topics: Anticarcinogenic Agents; Breast Neoplasms; Cell Death; Cell Line, Tumor; Diosgenin; Dose-Response Re | 2009 |
Sulforaphane inhibits prostate carcinogenesis and pulmonary metastasis in TRAMP mice in association with increased cytotoxicity of natural killer cells.
Topics: Angiogenesis Inhibitors; Animals; Anticarcinogenic Agents; Apoptosis; bcl-2-Associated X Protein; Ce | 2009 |
Cellular responses to cancer chemopreventive agent D,L-sulforaphane in human prostate cancer cells are initiated by mitochondrial reactive oxygen species.
Topics: Anticarcinogenic Agents; Apoptosis; Caspase 3; Cell Cycle; Cell Line, Tumor; Electron Transport; Gen | 2009 |
Gene expression profile of primary prostate epithelial and stromal cells in response to sulforaphane or iberin exposure.
Topics: Anticarcinogenic Agents; Cells, Cultured; Epithelial Cells; Gene Expression; Gene Expression Profili | 2009 |
D,L-Sulforaphane causes transcriptional repression of androgen receptor in human prostate cancer cells.
Topics: Androgen Receptor Antagonists; Anticarcinogenic Agents; Apoptosis; Humans; Immunoblotting; Isothiocy | 2009 |
Sulforaphane destabilizes the androgen receptor in prostate cancer cells by inactivating histone deacetylase 6.
Topics: Acetylation; Animals; Anticarcinogenic Agents; Histone Deacetylase 6; Histone Deacetylases; HSP90 He | 2009 |
Dietary sulforaphane, a histone deacetylase inhibitor for cancer prevention.
Topics: Acetylation; Animals; Anticarcinogenic Agents; Biological Availability; Brassica; Diet; Dietary Supp | 2009 |
The dietary isothiocyanate sulforaphane modulates gene expression and alternative gene splicing in a PTEN null preclinical murine model of prostate cancer.
Topics: Alternative Splicing; Animals; Apoptosis; Cell Cycle; Diet; Disease Models, Animal; Gene Deletion; G | 2010 |
Regulation of Nrf2- and AP-1-mediated gene expression by epigallocatechin-3-gallate and sulforaphane in prostate of Nrf2-knockout or C57BL/6J mice and PC-3 AP-1 human prostate cancer cells.
Topics: Animals; Anticarcinogenic Agents; Antineoplastic Combined Chemotherapy Protocols; Binding Sites; Cat | 2010 |
Sulforaphane increases drug-mediated cytotoxicity toward cancer stem-like cells of pancreas and prostate.
Topics: Aldehyde Dehydrogenase; Aldehyde Dehydrogenase 1 Family; Animals; Antineoplastic Combined Chemothera | 2011 |
Broccoli, PTEN deletion and prostate cancer: where is the link?
Topics: Animals; Brassica; Humans; Isothiocyanates; Male; Prostatic Neoplasms; PTEN Phosphohydrolase; Sulfox | 2010 |
Differential effects of sulforaphane on histone deacetylases, cell cycle arrest and apoptosis in normal prostate cells versus hyperplastic and cancerous prostate cells.
Topics: Acetylation; Anticarcinogenic Agents; Apoptosis; Cell Cycle; Cell Line; Cell Line, Tumor; Cyclin-Dep | 2011 |
Hydrogen sulfide mediates the anti-survival effect of sulforaphane on human prostate cancer cells.
Topics: Animals; Anticarcinogenic Agents; Cell Line, Tumor; Cell Survival; Cystathionine beta-Synthase; Cyst | 2011 |
Shattering the underpinnings of neoplastic architecture in LNCap: synergistic potential of nutraceuticals in dampening PDGFR/EGFR signaling and cellular proliferation.
Topics: Anticarcinogenic Agents; Antineoplastic Agents; Catechin; Cell Line, Tumor; Cell Proliferation; Curc | 2011 |
Sulforaphane, a cruciferous vegetable-derived isothiocyanate, inhibits protein synthesis in human prostate cancer cells.
Topics: Antineoplastic Agents, Phytogenic; Brassicaceae; Cell Line, Tumor; Cell Survival; Energy Metabolism; | 2012 |
Notch activation is dispensable for D, L-sulforaphane-mediated inhibition of human prostate cancer cell migration.
Topics: Cell Line, Tumor; Cell Movement; Humans; Isothiocyanates; Male; Prostatic Neoplasms; Receptors, Notc | 2012 |
Antiproliferative activity of the dietary isothiocyanate erucin, a bioactive compound from cruciferous vegetables, on human prostate cancer cells.
Topics: Adenocarcinoma; Anticarcinogenic Agents; Antineoplastic Agents, Phytogenic; Cell Line, Tumor; Cell P | 2013 |
The effect of indole-3-carbinol and sulforaphane on a prostate cancer cell line.
Topics: Anticarcinogenic Agents; Cell Physiological Phenomena; Colorimetry; Dose-Response Relationship, Drug | 2003 |
Sulforaphane induces caspase-mediated apoptosis in cultured PC-3 human prostate cancer cells and retards growth of PC-3 xenografts in vivo.
Topics: Animals; Anticarcinogenic Agents; Apoptosis; bcl-2-Associated X Protein; Caspases; Cell Division; Ce | 2004 |
Targeting cell cycle machinery as a molecular mechanism of sulforaphane in prostate cancer prevention.
Topics: Anticarcinogenic Agents; Apoptosis; Caspases; Cell Cycle; Cell Cycle Proteins; Cell Division; Cell L | 2004 |
Bax and Bak are required for apoptosis induction by sulforaphane, a cruciferous vegetable-derived cancer chemopreventive agent.
Topics: Animals; Anticarcinogenic Agents; Apoptosis; Apoptosis Regulatory Proteins; Apoptotic Protease-Activ | 2005 |
Sulforaphane-induced cell death in human prostate cancer cells is initiated by reactive oxygen species.
Topics: Acetylcysteine; Animals; Antioxidants; Apoptosis; BH3 Interacting Domain Death Agonist Protein; Carr | 2005 |
Suppression of NF-kappaB and NF-kappaB-regulated gene expression by sulforaphane and PEITC through IkappaBalpha, IKK pathway in human prostate cancer PC-3 cells.
Topics: Anticarcinogenic Agents; bcl-X Protein; Cell Line, Tumor; Cell Survival; Cyclin D1; Enzyme Inhibitor | 2005 |
Involvement of c-Jun N-terminal kinase in G2/M arrest and caspase-mediated apoptosis induced by sulforaphane in DU145 prostate cancer cells.
Topics: Anticarcinogenic Agents; Apoptosis; Caspases; Cell Cycle; Cell Division; Dose-Response Relationship, | 2005 |
ERK and JNK signaling pathways are involved in the regulation of activator protein 1 and cell death elicited by three isothiocyanates in human prostate cancer PC-3 cells.
Topics: Anticarcinogenic Agents; Apoptosis; Extracellular Signal-Regulated MAP Kinases; Food Preservatives; | 2006 |
Sulforaphane inhibits histone deacetylase activity in BPH-1, LnCaP and PC-3 prostate epithelial cells.
Topics: Androgens; Anticarcinogenic Agents; Apoptosis; Cell Cycle; Epithelial Cells; Histone Deacetylase Inh | 2006 |
Sulforaphane causes autophagy to inhibit release of cytochrome C and apoptosis in human prostate cancer cells.
Topics: Anticarcinogenic Agents; Apoptosis; Autophagy; Cell Line, Tumor; Cytochromes c; Humans; Isothiocyana | 2006 |
D,L-Sulforaphane-induced cell death in human prostate cancer cells is regulated by inhibitor of apoptosis family proteins and Apaf-1.
Topics: Anticarcinogenic Agents; Apoptosis; Apoptotic Protease-Activating Factor 1; Baculoviral IAP Repeat-C | 2007 |
Induction of p21 protein protects against sulforaphane-induced mitotic arrest in LNCaP human prostate cancer cell line.
Topics: Anticarcinogenic Agents; Cell Cycle; Cell Division; Cell Line, Tumor; Cyclin-Dependent Kinase Inhibi | 2007 |
Potent induction of phase 2 enzymes in human prostate cells by sulforaphane.
Topics: Anticarcinogenic Agents; Blotting, Northern; Brassica; Diet; Dose-Response Relationship, Drug; Enzym | 2001 |
Sulforaphane and its metabolite mediate growth arrest and apoptosis in human prostate cancer cells.
Topics: Anticarcinogenic Agents; Apoptosis; Cell Cycle; Cell Division; Cyclin D1; Dose-Response Relationship | 2002 |